[1]
PolistenaB., SpandonaroF., CapraR., FantacciniS., SantoniL., ZimatoreG. and GasperiniC. 2019. The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri® PharmacoEconomics (TyPE) Study. Global & Regional Health Technology Assessment. 6, 1 (Jun. 2019). DOI:https://doi.org/10.33393/grhta.2019.463.